Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 4

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 4
---
 the presentation, click on Grifols Q1 2025 Financial Results or visit the website
. Participants are advised to register in advance of the conference call.

Investors:

Investor Relations & Sustainability

Tel. +34 93 571 02 21

Page 3 of 4

Media:

Grifols Press Office

Tel. +34 93 571 00 02

About Grifols

Grifols is a global healthcare company
founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived
medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more
than 110 countries.

Patient needs and Grifols’ ever-growing
knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma
and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas:
immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry,
Grifols continues to grow its network of donation centers, the world’s largest with close to 400 across North America, Europe, Africa
and the Middle East, and China.

As a recognized leader in transfusion
medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to
clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing
pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and
healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees
in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation,
quality, safety, and ethical leadership.

In 2023, Grifols’ economic impact
in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company’s class A shares
are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed
on the Mercado Continuo (MCE:GRF.P) and on the U.S